Last updated 8 days ago
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
20000 patients around the world
Available in Chile, Argentina, Brazil
Janssen Research & Development, LLC
35Research sites
20000Patients around the world
This study is for people with
Cardiac arrhythmia
Atrial fibrillation
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Minimum age of 18 yearsMedically stable and appropriate for chronic antithrombotic treatmentAtrial fibrillation eligible to receive anticoagulationParticipant must satisfy one or both of the following categories of risk factors (a or b):a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of a clinical symptomatic stroke.b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure
- Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the studyAny condition other than AF that requires chronic anticoagulation
Sites
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
Instituto de Investigaciones Clínicas Tucumán
Recruiting
CIPADI - Centro Integral de Prevención y Atención en Diabetes
Recruiting
Hospital Vera Cruz
Recruiting
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA
Recruiting
Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP
Recruiting
Sociedade Hospitalar Angelina Caron
Recruiting
Instituto De Pesquisa Clinica de Campinas - Ipecc
Recruiting
Hospital Universitário de Canoas
Recruiting
StudyLIBREXIA-AF
SponsorJanssen Research & Development, LLC
Conditions
Atrial fibrillation
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05757869
